Tuesday, October 29, 2024

CATEGORY

Novo Nordisk

Breakthrough in Renewable Energy: Solar Technology Surges Ahead

In an era where climate concerns dominate global discourse, renewable energy sources stand at the forefront of sustainable solutions. Among these, solar energy has...

Alhemo® Receives Positive Recommendation for Haemophilia Treatment in Europe

Key TakeawaysNovo Nordisk's Alhemo® (concizumab) has received a positive opinion from the European Medicines Agency (EMA), marking it as the first once-daily subcutaneous...

Cell Therapy Advancements: Novo Nordisk and Evotec Partner for Next-Generation Treatments

Key TakeawaysNovo Nordisk's funding supports advanced cell therapy technology development at Evotec. The collaboration aims to produce off-the-shelf cell therapy products for clinical...

NanoVation Therapeutics and Novo Nordisk Forge Partnership to Develop Genetic Medicines for Cardiometabolic and Rare Diseases

Key TakeawaysNanoVation Therapeutics announced a multi-year partnership with Novo Nordisk aimed at developing genetic medicines for cardiometabolic and rare diseases. The collaboration focuses...

Medicare Spending on Wegovy Could Surge by $145 Billion

Key TakeawaysCovering Wegovy® (semaglutide) for heart disease risk could increase Medicare Part D spending by $34 billion to $145 billion annually. Medicare currently...

Novo Nordisk Faces Continued its GLP-1 Therapy Ozempic Shortages Into Q4 2024 Amid Expanding Demand

key Takeaways:Novo Nordisk announced that the shortage of lower doses of its GLP-1 therapy, Ozempic (semaglutide), is expected to continue into the fourth...

Novo Nordisk Reports Strong Financial Growth in H1 2024, Driven by Diabetes and Obesity Treatments

Key Takeaways:Novo Nordisk reported a 24% increase in sales and an 18% rise in operating profit for the first half of 2024, driven...

Heart Failure Approval Delayed as Novo Nordisk Withdraws Wegovy FDA Submission

Novo Nordisk has temporarily halted its pursuit of the Food and Drug Administration (FDA) approval for using its obesity drug Wegovy in treating heart...

Insulin Product Halt by Novo Nordisk Sparks Campaign to Save Levemir for Diabetics

Insulin production halt by Novo Nordisk has sparked a campaign by a patient advocacy group to stop the company from discontinuing the insulin product...

Reimbursement Denied: Healthcare Institute Declines Coverage for Wegovy for Obesity Due to Unclear Health Effects

Reimbursement for Wegovy, a new obesity medication containing the active substance semaglutide, has been advised against by the Dutch Healthcare Institute. Although Wegovy has...

Insulin Icodec Receives FDA Complete Response Letter, Additional Data Required for Approval

Insulin icodec a once-weekly basal insulin intended for the treatment of diabetes mellitus, has received a Complete Response Letter (CRL) from the Food and...

Diabetes Drug Battle: Novo Nordisk Confronts Generic Competition for Ozempic and Wegovy in China

Novo Nordisk is bracing for increased competition in the Chinese market, where at least 15 generic versions of its diabetes drug Ozempic and weight...

FDA Raises Hypoglycemia Concerns Over Novo Nordisk’s Weekly Insulin for Type 1 Diabetes

Blood sugar concerns were highlighted by the U.S. Food and Drug Administration (FDA) staff, noting that the use of Novo Nordisk's long-acting weekly insulin...

Wegovy Receives FDA Approval for Cardiovascular Events Reduction

Following a supplemental New Drug Application (sNDA) submitted by Novo Nordisk, the U.S. FDA has approved an expanded label for Wegovy reducing the risks...

FDA Consults Through Digital Health Technologies on Advancing Diabetes Detection with Industry Leaders

Dexcom and Novo Nordisk, leading entities in the healthcare sector, have actively engaged with the Food and Drug Administration (FDA) to promote the integration...

Latest news